For the quarter ended March 2024, Abbott (ABT) reported revenue of $9.96 billion, up 2.2% over the same period last year. EPS came in at $0.98, compared to $1.03 in the year-ago quarter.The reported revenue represents a surprise of +1.15% over the Zacks Consensus Estimate of $9.85 billion. With the consensus EPS estimate being $0.96, the EPS surprise was +2.08%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations ...

Abbott (ABT) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $1.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.08%. A quarter ago, it was expected that this maker of infant formula, medical devices and drugs would post earnings of $1.19 per share when it actually produced earnings of $1.19, delivering no surprise.Over the last four ...

Abbott Laboratories on April 17 reported a 2.2% rise of $10 billion in its 2024 first-quarter sales which includes the impact of the anticipated decline in COVID-19 testing-related sales as compared to the previous year.Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.Organic sales grew for the underlying base business of 10.8%, which represents the fifth consecutive quarter of double-digit growth. According to the report in the first quarter of 2024, ...

Financial Performance - Abbott reported first-quarter 2024 sales of $10.0 billion, reflecting a 2.2% increase year-over-year, with organic sales growth of 10.8% for the underlying base business[1]. - The company achieved a GAAP diluted EPS of $0.70 and an adjusted diluted EPS of $0.98, with full-year 2024 diluted EPS guidance narrowed to a range of $3.25 to $3.40[2]. - Abbott's full-year 2024 organic sales growth guidance, excluding COVID-19 testing-related sales, is now projected at 8.5% to 10.0%[2]. - Total worldwide sales for Q1 2024 were $9.964 billion, a 2.2% increase from $9.747 billion in Q1 2023[18]. - Net earnings for Q1 2024 were $1.225 billion, a decrease of 7.0% compared to $1.318 billion in Q1 2023[22]. - Diluted earnings per share for Q1 2024 were $0.70, down 6.7% from $0.75 in Q1 2023[22]. - Operating earnings for Q1 2024 were $1.386 billion, down 8.1% from $1.509 billion in Q1 2023[22]. - U.S. revenue decreased by 2.1% to $3,846 million in Q1 2024 from $3,928 million in Q1 2023[33]. - International revenue increased by 5.2% to $6,118 million in Q1 2024, up from $5,819 million in Q1 2023[33]. - Organic growth for the total company was reported at 4.7% for Q1 2024[33]. Sales Performance by Segment - Worldwide Nutrition sales increased 5.1% on a reported basis and 7.7% on an organic basis in Q1 2024, with Pediatric Nutrition sales growing 9.2% reported and 10.5% organic[5][6]. - Diagnostics sales were reported at $2.214 billion, a decline of 17.6% year-over-year, primarily due to a decrease in COVID-19 testing sales, which were $204 million compared to $730 million in the prior year[7][8]. - Established Pharmaceuticals sales increased 3.1% on a reported basis and 13.7% on an organic basis, driven by growth in key emerging markets[9][10]. - Medical Devices sales reached $4.453 billion, reflecting a 14.2% increase on a reported basis and 14.3% organic growth, with double-digit growth in both U.S. and international markets[11]. - FreeStyle Libre sales in Diabetes Care reached $1.5 billion, reflecting a 22.4% growth on a reported basis and 23.3% on an organic basis[12]. - In Electrophysiology, international sales grew 18.9% reported and 23.0% organic, with Europe seeing a 20.4% organic growth[12]. - Total Medical Devices revenue reached $4,453 million in Q1 2024, a 14.2% increase from $3,900 million in Q1 2023[33]. - Vascular segment revenue was $689 million in Q1 2024, reflecting an 11.7% increase compared to $617 million in Q1 2023[33]. - The international Medical Devices segment showed a strong organic growth of 16.1% in Q1 2024[33]. Research and Development - Research and development expenses increased by 4.5% to $684 million in Q1 2024 compared to $654 million in Q1 2023[22]. Corporate Actions - Abbott launched the Protality™ brand, a new high-protein nutrition shake, and received FDA approval for the TriClip™ treatment for tricuspid regurgitation in April 2024[2]. - The company completed enrollment in the Volt CE Mark clinical study for the Volt™ Pulsed Field Ablation System, aimed at treating heart rhythm disorders[2]. - The company declared a quarterly dividend of $0.55 per share, marking 401 consecutive quarterly dividends and 52 years of dividend increases[14]. Costs and Expenses - Abbott's total operating costs and expenses rose by 4.1% to $8.578 billion in Q1 2024 from $8.238 billion in Q1 2023[22]. - The company incurred $518 million in specified items, including $472 million for intangible amortization and $42 million for restructuring initiatives[35]. - Abbott's gross margin was impacted by acquisition-related expenses and restructuring costs totaling $518 million[35].

Sales of $10.0 billion driven by strong underlying base business performance Reported sales increased 2.2 percent, which includes the impact from the anticipated decline in COVID-19 testing-related sales versus prior year Organic sales growth for underlying base business of 10.8 percent, which represents the fifth consecutive quarter of double-digit growth1 ABBOTT PARK, Ill., April 17, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2024. ...

Tuesday, April 16th, 2024Market indices fluctuated today. The S&P 500 and Nasdaq were in-line throughout the day, right around breakeven (-0.21% and -0.12%, respectively). The Dow stayed in the green for all but a few minutes on the session, finishing +0.17%. The Russell 2000 only spent a moment out of negative territory today, reaching the closing bell at -0.42%. Fed Chair Jerome Powell’s comments today solidified that monetary policy is seriously considering delaying its first rate cut until economic repo ...

LAS VEGAS, NEVADA - JANUARY 10: An Abbott logo is displayed at the company's booth during CES 2024 ... [+] at the Las Vegas Convention Center on January 10, 2024 in Las Vegas, Nevada. (Photo by Ethan Miller/Getty Images)Getty ImagesAbbott (NYSE: ABT) will report its Q1 2024 results on Wednesday, April 17. We expect the company to post revenue of $9.9 billion and earnings of $0.95 on a per share and adjusted basis, aligning with the street expectations. We expect a low double-digit uptick in sales for the co ...

With the Q1 earnings season underway, there will be a microscope on companies that can continue to show improvements in their outlook amid an uptick in inflation.That said, several top-rated Zacks stocks are standing out before their quarterly report next week, and here are three to consider.  Interactive Brokers (IBKR) First quarter results from Interactive Brokers on Tuesday, April 16 are expected to reflect considerable growth in the global electronic security exchange providers' top and bottom lines. Qu ...

Abbott Laboratories (ABT) is slated to report its first-quarter 2024 results on Apr 17, before market open.The company posted adjusted earnings per share (EPS) of $1.19 in the last reported quarter, which matched the Zacks Consensus Estimate. In the trailing four quarters, its earnings exceeded the Zacks Consensus Estimate on three occasions and came in line on one occasion, the average beat being 3.15%.Let's see how things have shaped up prior to this announcement.Factors at PlayEstablished Pharmaceuticals ...

With rising concerns in the market potentially forcing a strategic shift, investors may want to consider healthcare stocks. No matter what happens, people need access to health-related products and services. It’s one of the essentials of life, which makes the industry such a politically sensitive matter.Besides the critical need, another element that helps bolster the case for healthcare stocks is the underlying diversity. Yes, the sector centers on the pharmaceutical innovation space. However, the arena co ...